Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10
Autor: | Charlotte Hindsberger, Pierre Johansen, Yasmin Ghani, Esteban Jódar, Matthew Capehorn |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Randomised controlled trials 030209 endocrinology & metabolism Subgroup analysis Type 2 diabetes 030204 cardiovascular system & hematology 03 medical and health sciences Diabetes mellitus 0302 clinical medicine Internal medicine Post-hoc analysis Endocrinología Internal Medicine medicine Metformina Adverse effect Original Research Sulphonylurea business.industry Semaglutide Oral antidiabetic agents GLP-1RA medicine.disease Metformin Discontinuation Sistema endocrino Tolerability business Diabetes care |
Zdroj: | Diabetes Therapy ABACUS. Repositorio de Producción Científica Universidad Europea (UEM) |
ISSN: | 1869-6961 1869-6953 |
Popis: | Introduction Despite treatment with oral antidiabetic drugs (OADs), achieving effective glycaemic control in type 2 diabetes (T2D) remains a challenge. The objective of this post hoc analysis of data from the SUSTAIN 2, 3, 4 and 10 active-controlled trials was to assess the efficacy and safety of the once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide in patients on background treatment with metformin (MET), with or without a sulphonylurea (SU). Methods Data from the randomised phase 3 trials SUSTAIN 2, 3, 4 and 10 for subjects who received background MET alone or MET + SU were analysed. Change from baseline in HbA1c and body weight at the end of treatment visit (week 30 in SUSTAIN 4 and 10, week 56 in SUSTAIN 2 and 3), and rates of hypoglycaemia and adverse events leading to premature treatment discontinuation were assessed. Results In total, 3411 subjects were included in the full analysis set (3410 in the safety analysis set). Across the four trials, semaglutide significantly reduced HbA1c (estimated treatment difference [ETD] − 0.32 to − 0.79%-points for semaglutide 0.5 mg, and − 0.38 to − 1.07%-points for semaglutide 1.0 mg vs comparators; p |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |